Research programme: recombinant mycobacteria - Bacilligen

Drug Profile

Research programme: recombinant mycobacteria - Bacilligen

Alternative Names: rBGC; rMB

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bacilligen
  • Class Bacterial vaccines; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bladder cancer; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 13 Nov 2007 Preclinical trials in Bladder cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top